NCT06975865

The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease

RecruitingPHASE3INTERVENTIONAL

Trial Details

Start: 2025-08-12Est. Completion: 2027-07-23

Enrollment target: 192 participants

Locations

University of Alabama at Birmingham- Site Number : 8400003, Birmingham, Alabama, United States
Phoenix Children's Hospital- Site Number : 8400028, Phoenix, Arizona, United States
University of California San Francisco- Site Number : 8400040, Fresno, California, United States
Oncology & Hematology Associates of West Broward- Site Number : 8400029, Coral Springs, Florida, United States
Sylvester Comprehensive Cancer Center- Site Number : 8400020, Miami, Florida, United States
University of Illinois-Chicago - College of Medicine- Site Number : 8400054, Chicago, Illinois, United States
Indiana University Health Riley Hospital for Children- Site Number : 8400056, Indianapolis, Indiana, United States
Louisiana State University Health Sciences Center - Shreveport- Site Number : 8400037, Shreveport, Louisiana, United States
University of Maryland School of Medicine - Baltimore- Site Number : 8400041, Baltimore, Maryland, United States
University of Michigan Health System - Ann Arbor- Site Number : 8400035, Ann Arbor, Michigan, United States
Southern Specialty Research- Site Number : 8400059, Flowood, Mississippi, United States
Richmond University Medical Center- Site Number : 8400038, Staten Island, New York, United States

Sickle Cell DiseaseBeta-thalassemia

This is a non-ablative (partial) stem cell transplant for patients with severe sickle cell disease or beta-thalassemia r…

Bethesda, United StatesEst. completion Jun 30, 2032

Sickle Cell Disease

The purpose of this study is to determine whether giving extra arginine to patients with sickle cell disease seeking tre…

Atlanta, United StatesEst. completion Jan 2028

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.